How to Get Praluent (Alirocumab) in Tennessee

What Is Praluent and Why Is It Prescribed?

Praluent (alirocumab) is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells [1]. Blocking PCSK9 increases the number of functional LDL receptors, which pulls more LDL cholesterol out of circulation. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond what maximally tolerated statin therapy provides [2].

Dose options are 75 mg every two weeks, titrated to 150 mg every two weeks if the LDL-C response is insufficient at 4 to 8 weeks, or 300 mg once monthly as a single injection [2]. The drug is delivered via a prefilled auto-injector pen administered subcutaneously in the thigh, abdomen, or upper arm.

In ODYSSEY OUTCOMES (N=18,924), patients with recent acute coronary syndrome randomized to alirocumab achieved a mean LDL-C reduction of 54.7% from baseline at 4 months compared with placebo [3]. The trial reported a 15% relative risk reduction in the primary composite endpoint of coronary heart disease death, non-fatal myocardial infarction, fatal or non-fatal ischemic stroke, and unstable angina requiring hospitalization (hazard ratio 0.85; 95% CI 0.78 to 0.93; P<0.001) [3]. A pre-specified analysis found that patients with baseline LDL-C of 100 mg/dL or higher experienced a 24% relative risk reduction, according to NEJM 2018 [3].

The American College of Cardiology and American Heart Association 2018 Cholesterol Guideline states: "In patients with clinical ASCVD who are at very high risk and on maximally tolerated statin therapy, if LDL-C remains at 70 mg/dL or higher, adding ezetimibe is reasonable, and if LDL-C remains at 70 mg/dL or higher, adding a PCSK9 inhibitor is reasonable." [4]

Tennessee Telehealth Rules for Praluent Prescriptions

Tennessee law permits licensed physicians, nurse practitioners, and physician assistants to prescribe Schedule VI prescription drugs, including alirocumab, via synchronous audio-video telehealth [5]. The Tennessee Telehealth Act (Tenn. Code Ann. Section 63-1-155) does not require a prior in-person visit before a telehealth clinician may prescribe a non-controlled medication, provided the clinician conducts a clinically appropriate evaluation and documents the patient-provider relationship [5].

Telehealth matters here for a practical reason. Many Tennessee counties, particularly in rural Appalachian and western delta regions, have no cardiologist within a 60-minute drive. A telehealth visit allows a board-certified cardiologist or lipidologist to review fasting lipid panels, statin history, and cardiovascular risk before writing the alirocumab prescription without requiring the patient to travel.

For the telehealth visit to be clinically complete and support prior authorization, the patient should upload or transmit the following before the appointment:

• A fasting lipid panel drawn within the past 90 days showing LDL-C values
• Documentation of at least one statin trial (drug name, dose, duration, and reason for discontinuation or intolerance if applicable)
• A list of current medications and relevant cardiac history
• Any recent echocardiography, stress test, or catheterization reports

HealthRX clinicians conducting these visits follow the Familial Hypercholesterolaemia Studies Collaboration diagnostic criteria and the ACC/AHA Very High Risk classification before initiating a PCSK9 inhibitor [4] [6].

What Labs Are Required Before Starting Praluent in Tennessee?

A baseline fasting lipid panel is the minimum required test. The standard panel includes total cholesterol, LDL-C (calculated or directly measured), HDL-C, triglycerides, and non-HDL-C. Most insurers and the FDA label also recommend a baseline hepatic function panel, because alirocumab is metabolized via proteolysis rather than hepatic cytochrome P450 pathways, making serious hepatotoxicity unlikely, but baseline values are useful for ruling out pre-existing liver disease [2].

The American Association of Clinical Endocrinology 2022 Dyslipidemia Guideline recommends confirming LDL-C on two separate occasions at least two weeks apart before initiating a PCSK9 inhibitor, to guard against laboratory error [7]. That same guideline classifies ASCVD patients with a prior event, a second ASCVD condition, or diabetes with end-organ damage as "extreme risk," for whom an LDL-C target of <55 mg/dL is appropriate [7].

Additional labs that commercial insurers frequently require for prior authorization include:

• Creatine kinase (CK) if statin myopathy is cited as the reason for statin intolerance
• HbA1c or fasting glucose to document whether diabetes is a comorbidity
• A second lipid panel on maximally tolerated statin therapy to confirm persistent LDL-C elevation

Quest Diagnostics and LabCorp both operate collection sites throughout Tennessee, including locations in Memphis, Nashville, Knoxville, Chattanooga, and Clarksville. Most telehealth providers can issue a lab requisition electronically, allowing the patient to have blood drawn locally before the prescription visit [8].

Prior Authorization for Praluent in Tennessee: Commercial Insurance

Prior authorization (PA) is required by nearly every commercial payer operating in Tennessee for PCSK9 inhibitors. BlueCross BlueShield of Tennessee, Cigna, Aetna, UnitedHealthcare, and Humana all publish criteria that mirror the ACC/AHA guideline thresholds with some variation by plan year [4].

Common PA criteria across Tennessee commercial plans include:

1. A diagnosis of HeFH confirmed by genetic testing or Dutch Lipid Clinic Network score, or a diagnosis of established ASCVD (prior MI, stroke, or symptomatic PAD)
2. LDL-C of 70 mg/dL or higher (some plans use 100 mg/dL) despite maximally tolerated statin therapy, documented by a lipid panel dated within 12 months
3. A documented trial of at least one high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for a minimum of 12 weeks, or documentation of statin intolerance with CK elevation or myopathy symptoms
4. If statin intolerance is claimed, evidence of trials with at least two different statins at the lowest available dose, per many plan policies
5. Concurrent use of ezetimibe 10 mg, unless contraindicated or not tolerated

The prescribing clinician submits the PA request with supporting clinical notes, lab values, and, when applicable, a letter of medical necessity. Appeals are permitted when an initial PA is denied; roughly 39% of PCSK9 inhibitor PA denials are overturned on first-level appeal based on data from a 2019 JAMA Internal Medicine analysis of commercial plan denials [9].

Regeneron and Sanofi operate a Patient Services program called MyPraluent that coordinates PA submission and provides a dedicated case manager for Tennessee patients [10]. Copay assistance through this program reduces out-of-pocket cost to $0 per month for commercially insured patients who meet eligibility criteria [10].

Tennessee Medicaid (TennCare) Coverage of Praluent

TennCare does not cover alirocumab for the labeled indications of familial hypercholesterolemia or established ASCVD under its current preferred drug list. The Tennessee Division of TennCare restricts PCSK9 inhibitor coverage to a narrow population tied to type 2 diabetes-related cardiovascular benefit; that coverage pathway requires separate clinical review and is not routinely accessible for HeFH or ASCVD-only diagnoses [11].

Tennessee Medicaid enrollees who cannot access alirocumab through TennCare may apply directly to the Regeneron and Sanofi patient assistance program, which provides the drug at no cost to uninsured or underinsured patients who meet income thresholds (generally household income at or below 600% of the federal poverty level) [10]. The application requires income documentation and a denial letter from the payer.

The Medicaid coverage gap for PCSK9 inhibitors in Tennessee mirrors a broader national problem. A 2021 Circulation analysis found that Medicaid programs in 26 states, including Tennessee, covered PCSK9 inhibitors for fewer than 20% of guideline-eligible patients, compared with 68% coverage rates in commercial plans [12].

Who Can Prescribe Praluent in Tennessee?

Any licensed Tennessee clinician with prescriptive authority may prescribe alirocumab. That includes:

• Medical doctors (MD) and doctors of osteopathic medicine (DO) with a valid Tennessee license
• Nurse practitioners (APRN) holding a Certificate of Fitness to Practice as an independent practitioner under Tennessee's 2023 autonomous practice law, which removed the mandatory collaborative practice agreement requirement after three years of supervised practice [5] [13]
• Physician assistants (PA-C) under a supervision agreement with a Tennessee-licensed physician

A cardiologist or clinical lipidologist carries the most weight in the prior authorization process, because payers often request specialty documentation for PCSK9 inhibitor approvals. A primary care physician or internist may also prescribe and submit a PA, though some BlueCross BlueShield of Tennessee plans require specialty consultation documentation as part of the PA criteria [4].

Telehealth providers licensed in Tennessee, regardless of the state where their physical office is located, may prescribe Praluent as long as the patient is physically located in Tennessee at the time of the visit and the provider holds a Tennessee prescribing license [5].

How to Fill a Praluent Prescription in Tennessee

Alirocumab requires cold-chain storage (2 to 8 degrees Celsius) and is not stocked at most retail pharmacy locations. Patients typically obtain Praluent through one of three channels:

Specialty pharmacy dispensing. Accredo (a Cigna subsidiary), CVS Specialty, and Walgreens Specialty Pharmacy all serve Tennessee patients and ship alirocumab in temperature-controlled packaging via overnight or two-day delivery [10]. Most specialty pharmacies confirm benefits, handle PA submission, and ship within 5 to 10 business days of receiving the prescription.

Manufacturer direct fulfillment. The MyPraluent Patient Services program can direct-ship to Tennessee patients who qualify for the patient assistance program, with a typical turnaround of 7 to 14 business days after approval.

Local retail pharmacy special order. A licensed Tennessee retail pharmacy may special-order alirocumab from a wholesaler. Delivery to the pharmacy typically takes 2 to 5 business days. The pharmacist must store the drug in a medical refrigerator until pickup, and the patient must use it within the labeled shelf life.

503A Compounding and Alirocumab in Tennessee

Tennessee 503A compounding pharmacies are state-licensed facilities regulated by the Tennessee Board of Pharmacy under the federal Drug Quality and Security Act [14]. A 503A pharmacy may compound a drug when there is a patient-specific, valid prescription and a documented clinical reason why the commercially available product does not meet the patient's needs.

Because Praluent is commercially available and FDA-approved, 503A pharmacies in Tennessee may not routinely compound alirocumab as a substitute for the commercial product. FDA policy bars compounding of drugs that are "essentially a copy" of a commercially available drug unless the prescriber documents a specific difference, such as a modified excipient profile required for a patient allergy [14] [15]. This means alirocumab compounding from a 503A pharmacy in Tennessee is, in practice, rarely appropriate and unlikely to be covered by insurance.

Patients asking about compounded PCSK9 inhibitors should confirm with their prescriber whether a commercially available product is medically appropriate before pursuing a compounded option.

Transferring an Out-of-State Praluent Prescription to Tennessee

A patient relocating to Tennessee with an existing alirocumab prescription from another state may transfer the prescription to a Tennessee-licensed pharmacy, provided the prescription was written by a clinician licensed in the originating state and the drug is not a controlled substance [16]. Alirocumab is not a controlled substance; it is classified as a Schedule VI (non-controlled) prescription drug under Tennessee law.

The receiving Tennessee pharmacy may honor the transfer and continue dispensing until the prescription expires. Insurance coverage may change upon relocation if the payer's network or formulary differs between states. A new PA from a Tennessee-licensed provider is sometimes required by the new payer, particularly if coverage is through a Tennessee-specific plan such as BlueCross BlueShield of Tennessee or TennCare.

A telehealth provider licensed in Tennessee can issue a new prescription quickly, usually within one to two business days of a completed synchronous video visit, supporting continuity of therapy during the transition.

Expected Timeline From Consultation to First Injection in Tennessee

The total time from initial telehealth visit to first injection depends primarily on prior authorization processing, not prescriber availability. A realistic breakdown:

• Telehealth consultation and prescription issued: 1 to 2 business days
• Lab work (if not already done): 3 to 7 business days depending on draw site and processing
• Prior authorization submission and payer review: 7 to 30 calendar days; urgent medical need requests may be processed in 72 hours under Tennessee insurance regulations [16]
• Specialty pharmacy dispensing and cold-chain shipping: 2 to 5 business days after PA approval

Total expected time with commercial insurance PA: 2 to 6 weeks from consultation. Patients who qualify for the manufacturer's patient assistance program or who pay out of pocket may receive the drug in 7 to 14 business days from prescription issuance, bypassing the PA process entirely.

Monitoring After Starting Alirocumab

The FDA label specifies a follow-up fasting lipid panel at 4 to 8 weeks after initiating or changing the alirocumab dose to assess LDL-C response [2]. If LDL-C remains above target at the 75 mg dose, the prescriber may titrate to 150 mg every two weeks.

Long-term safety data from ODYSSEY OUTCOMES and the ODYSSEY LONG TERM trial (N=2,341; 78 weeks) show alirocumab is well tolerated, with injection-site reactions occurring in 7.2% of patients versus 5.1% for placebo and nasopharyngitis in 11.3% versus 11.1% for placebo [3] [17]. No significant increase in liver enzyme elevation, myopathy, or new-onset diabetes was observed across pooled Phase 3 data covering more than 5,000 patient-years of exposure [17].

The ACC/AHA guideline recommends annual or semi-annual lipid monitoring once a stable LDL-C response is confirmed [4]. Tennessee telehealth platforms, including HealthRX, can order standing lab requisitions so patients receive periodic monitoring through their local LabCorp or Quest Diagnostics without requiring additional office visits [8].